Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.
CARTITUDE-1: Redefining the Trajectory of Treatment for Relapsed/Refractory Multiple Myeloma (RRMM)
June 27th 2025Panelists discuss how 5-year follow-up data from the CARTITUDE-1 study demonstrate that chimeric antigen receptor T-cell therapy with ciltacabtagene autoleucel achieved durable remissions in heavily pretreated patients with multiple myeloma, with 30% remaining progression free at 5 years and some patients achieving what may be considered a functional cure, potentially transforming multiple myeloma from an incurable to a curable disease.
Circulating Tumor DNA in Colorectal Cancer: Insights From the SWOG 80702 and BESPOKE Studies
March 31st 2025John Marshall, MD, and Mark Lewis, MD, discuss how circulating tumor DNA (ctDNA) testing in colorectal cancer offers promising clinical utility across the care continuum, from early detection to treatment monitoring, with trials like BESPOKE and SWOG 80702 demonstrating its potential to guide personalized therapy decisions, predict outcomes based on minimal residual disease status, complement traditional imaging in challenging cases, and transform patient care through a patient-centric approach that requires ongoing research to establish standardized protocols.
PALOMA-3: Subcutaneous Amivantamab + Lazertinib for EGFR+ NSCLC
December 20th 2024Joshua K. Sabari, MD, and Martin Dietrich, MD, PhD, examine both the evolution of first-line EGFR TKIs as standard treatment for EGFR-mutated metastatic non-small cell lung cancer and the ongoing clinical challenges in managing resistance, toxicities, and treatment sequencing in this space.
Pelabresib in Myelofibrosis: Exploring Disease Modification and Immune Response
September 19th 2024Panelists discuss how myelofibrosis management involves a blend of medications, supportive care, and potential stem cell transplantation, with a focus on Janus kinase inhibitors and investigational agents like pelabresib for modifying disease progression, as well as the findings from the MANIFEST-2 trial regarding spleen volume reduction and biomarker data.
IMbrave150: Atezolizumab plus Bevacizumab in HCC: Efficacy Data and Clinical Practice Implications
August 23rd 2024Rahul Gosain, MD; Rohit Gosain, MD, and Daniel Ahn, DO, analyze pivotal studies in hepatocellular carcinoma, including HIMALAYA, IMbrave 150, and CheckMate 9DW, discussing study designs, outcomes, patient characteristics, and efficacy data.